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Abstract
Introduction: Randomized trials investigating neuromuscular blocking agents in adult acute respiratory distress
syndrome (ARDS) have been inconclusive about effects on mortality, which is very high in this population.
Uncertainty also exists about the associated risk of ICU-acquired weakness.
Methods: We conducted a systematic review and meta-analysis. We searched the Cochrane (Central) database,
MEDLINE, EMBASE, ACP Journal Club, and clinical trial registries for randomized trials investigating survival effects of
neuromuscular blocking agents in adults with ARDS. Two independent reviewers abstracted data and assessed
methodologic quality. Primary study investigators provided additional unpublished data.
Results: Three trials (431 patients; 20 centers; all from the same research group in France) met inclusion criteria for
this review. All trials assessed 48-hour infusions of cisatracurium besylate. Short-term infusion of cisatracurium
besylate was associated with lower hospital mortality (RR, 0.72; 95% CI, 0.58 to 0.91; P = 0.005; I2 = 0). This finding
was robust on sensitivity analyses. Neuromuscular blockade was also associated with lower risk of barotrauma (RR,
0.43; 95% CI, 0.20 to 0.90; P = 0.02; I2 = 0), but had no effect on the duration of mechanical ventilation among
survivors (MD, 0.25 days; 95% CI, 5.48 to 5.99; P = 0.93; I2 = 49%), or the risk of ICU-acquired weakness (RR, 1.08;
95% CI, 0.83 to 1.41; P = 0.57; I2 = 0). Primary studies lacked protracted measurements of weakness.
Conclusions: Short-term infusion of cisatracurium besylate reduces hospital mortality and barotrauma and does
not appear to increase ICU-acquired weakness for critically ill adults with ARDS.
Introduction
Acute respiratory distress syndrome (ARDS) is a com-
mon and life-threatening condition that complicates a
variety of critical illnesses, including sepsis, pneumonia,
and trauma. Characterized by intense lung inflamma-
tion, consolidation, and progressive microatelectasis,
ARDS is associated clinically with severe hypoxemia,
patient-ventilator dyssynchrony, and high susceptibility
to barotrauma and ventilator-induced lung injury.
Approximately 140,000 patients are affected by ARDS
annually in the United States alone [1]. Despite advances
in the relevant technology and research methods, mor-
tality from ARDS remains as high as 26% to 58% [2,3].
Although relatively few interventions may improve sur-
vival for patients with ARDS, the interventions with most
supportive research findings are ventilation strategies
that aim to minimize ventilator-induced lung injury. In a
landmark clinical trial, low-tidal-volume ventilation was
found to improve survival for critically ill adults with
acute lung injury or ARDS [4], and a systematic review of
10 related randomized trials supports this finding [5].
Whereas a lung-protective role for high levels of PEEP in
adult ARDS is less clear, a patient-level meta-analysis
including 2,299 participants from three trials suggests
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lower mortality, particularly for moderate to severe ARDS
[6]. Prone ventilation may also have a lung-protective
effect [7]. Similarly, neuromuscular blocking agents
(NMBAs) may have an important role in the management
of critically ill adults with ARDS.
Clinicians commonly rely on NMBAs in the manage-
ment of ARDS to prevent patient-ventilator dyssynchrony,
to minimize the work of breathing, and to improve oxyge-
nation [8-11]. Indeed, an early, small, randomized trial
demonstrated improved oxygenation with continuous cisa-
tracurium therapy [12]. In a subsequent trial, the same
group of investigators found a statistically significant
reduction in inflammatory biomarkers in both the blood
and bronchoalveolar fluid of patients treated with cisatra-
curium, along with improved oxygenation [13]. Recently,
they reported a trial of 339 patients that did not show a
statistically significant reduction in crude hospital mortal-
ity [14]. These potential benefits must be weighed against
prevailing concerns about NMBA therapy, including pro-
gressive atelectasis due to loss of diaphragmatic tone (with
resultant hypoxemia) and, most important, ICU-acquired
weakness [15,16]. Those concerns previously led one
guideline panel to suggest NMBAs as a consideration only
in the setting of severe hypoxemia [17], and another to
recommend avoiding NMBAs [18].
Given the uncertain role for NMBAs in the management
of adults with ARDS, we conducted a systematic review
and a meta-analysis, including previously unpublished
data, to clarify the effects of NMBA on mortality and
other clinically important outcomes.
Materials and methods
By following a prespecified research protocol, this review
included parallel-group randomized trials investigating the
administration of any NMBA to mechanically ventilated
adults with ARDS, as defined by American-European
Consensus Conference (AECC) [19], regardless of the
underlying etiology, and dating back to 1966. Outcomes of
interest included measures of mortality at 28 days, ICU
discharge, and hospital discharge (primary outcome);
duration of mechanical ventilation (in all patients and in
survivors), ventilator-free days (VFDs), ICU and hospital
stay; changes in oxygenation (measured by using the PO2/
FiO2 ratio); ICU-acquired weakness; and barotrauma
(including pneumothorax, pneumomediastinum, pneuma-
tocele, and subcutaneous emphysema).
Search strategy
Computerized literature searches included MEDLINE
(1966 to October 2012), EMBASE (1980 to October
2012), ACP Journal Club (1991 to October 2012), the
Cochrane (Central) database, and clinical trial registries
(clinicaltrials.gov, ISRCTN Register, and WHO ICTRP)
(see Additional file 1). Relevant conference proceedings
were searched electronically through a specific service
provided through McMaster University [20].
Study selection and data extraction
Two reviewers (WA and MA) independently screened
titles and abstracts in duplicate, without language restric-
tion. The same duplicate, independent review process was
followed by reviewing the full text of all potentially eligible
articles; by reviewing citation lists of these articles for
additional studies; and abstracting data (related to out-
comes, or to risk of bias) onto customized, pretested
forms. To resolve disagreements, we contacted study
authors. For the purposes of this review, study authors
provided unpublished data related to hospital mortality
(truncated at 90 days), duration of mechanical ventilation,
VFDs, and gas exchange.
Assessment of risk of bias of included studies
For each trial, reviewers used the Cochrane Risk of Bias
tool to judge the adequacy of randomization, conceal-
ment, blinding, and outcome-data completeness, and to
check for selective outcome assessments and other pos-
sible sources of bias [21]. Reviewers judged the risk of
bias in each of these domains as high risk, low risk, or
unclear. The overall risk of bias for an individual trial
was categorized as low when the risk of bias was low in
all domains; unclear when the risk of bias was unclear
in at least one domain, with no high-risk domains; or
high when the risk of bias was high in at least one
domain.
Statistical analysis
We pooled data by using RevMan 5.1 and random-effects
models, applying inverse variance weighting and the
methods of DerSimonian and Laird [22]. We generated
summary estimates of relative risk (RR) for dichotomous
outcomes and mean differences (MDs) for continuous
outcomes, each with associated 95% confidence intervals
(CIs). To investigate the effect of treatment on oxygena-
tion, we analyzed early changes in PaO2/FiO2 at 24, 48,
and 72 hours after randomization. To assess for effects
on duration of ventilation, we planned to compare VFDs
at day 28. Because of the controversy surround VFDs as
an outcome, we conducted post hoc comparisons of dura-
tion of ventilation in survivors, and all patients. We
assessed for heterogeneity between studies by using the
Mantel-Haenszel c2 statistic (P < 0.01 indicating substan-
tial heterogeneity) and the I2 statistic (> 50% indicating
substantial heterogeneity). We had too few studies to
assess for publication bias by using a funnel plot or con-
ventional statistical methods [23].
The review protocol stipulated a number of explora-
tory analyses to assess potential reasons for differing
results (if any) across studies. We hypothesized that two
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factors might generate estimates of greater benefit: high
or unclear risk of bias (versus low), and more-severe
hypoxemia at baseline (PO2//FiO2 < 100, versus 100 to
200). To inform current guidelines, we also sought to
estimate the effect of NMBA specifically among sepsis
patients. With RevMan 5.1 software, subgroup analyses
were conducted by pooling RRs for subgroups in each
trial. Last, we planned to test the robustness of our pri-
mary (mortality) results in sensitivity analyses by using
fixed-effects models and by using two alternative statisti-
cal metrics: odds ratios and risk differences. To estimate
the number of adults with ARDS that must receive
NMBA therapy to save one additional life (number need
to treat), we assumed a mortality rate of 40% in the
absence of NMBA therapy, in accordance with mortality
rates in current trials [14].
After judging the risk of bias for each study, and pooling
results across studies, we judged the quality of the totality
of the evidence addressing the role for NMBAs in the
management of ARDS. We used the Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) approach, which considers (a) risk of bias in
individual trials, (b) consistency of results across trials),
(c) potential for publication bias, (d) precision of pooled
estimates, and (e) suitability of the individual study popu-
lations, interventions, and outcome assessments in directly
addressing the question of this review [24].
Results
After screening 740 titles and abstracts, we found three
trials eligible for this review (Figure 1). All three trials ori-
ginated from the same group of investigators, including a
total of 431 patients, and one trial was conducted in
20 centers in France. The trials were specifically designed
to investigate the effects of cisatracurium besylate, a ben-
zylisoquinoline compound, on gas exchange [12], inflam-
matory markers [13], and clinically important outcomes
[14], respectively. In each trial, cisatracurium besylate was
infused for 48 hours, by using weight-based dosing in two
trials [12,13], and a fixed high dose (15 mg bolus, followed
by a continuous infusion of 37.5 mg per hour) in the other
(Table 1) [14]. All three trials reported 28-day mortality,
barotraumas, and ICU-acquired weakness; and these data
were supplemented by additional, previously unpublished
data from the study investigators.
In terms of the quality of individual trials, one trial
had low risk of bias [14]; the other two were judged to
be at high risk of bias because of limitations in blinding
(Table 2). In each trial, physicians and nurses ascertained
that study patients were deeply sedated (with no response
to glabellar tap) before initiating the study infusion. In
two trials, the study drug-infusion bag (containing either
cisatracurium besylate or normal saline) was concealed
by a sheet, and the only caregivers explicitly aware of
treatment allocation were bedside nurses caring for study
participants during the 48 hours of study infusion.
Nurses were responsible for the assessment of neuromus-
cular blockade (at 8-hour intervals during the study infu-
sion and the following 24 hours) and for the protocolized
delivery of sedation and cisatracurium besylate. The most
recent trial included a more-robust placebo. Study infu-
sion bags contained identical solutions of cisatracurium
besylate or normal saline, prepared outside of the hospi-
tal; peripheral nerve stimulators were not used to assess
depth of paralysis; nurses assessed plateau airway pres-
sure to determine whether additional study drug was
required.
Cisatracurium besylate was associated with lower risk
of death at 28 days (RR, 0.66; 95% CI, 0.50 to 0.87; P =
0.003; I2 = 0; Figure 2), at ICU discharge (RR, 0.70; 95%
CI, 0.55 to 0.89; P = 0.004; I2 , 0; Figure 2), and at hos-
pital discharge (RR, 0.72; 95% CI, 0.58 to 0.91; P =
0.005; I2 = 0; Figure 2). Assuming a mortality rate of
40% in the absence of cisatracurium therapy at each of
these time points, these pooled estimates suggest a
number needed to treat of seven patients (95% CI, 5 to
19) to save one additional life at 28 days; eight patients
(95% CI, 4 to 31) to save one additional life at ICU dis-
charge; and nine patients (95% CI, 6 to 27) for hospital
mortality (Table 3).
NMBA therapy was also associated with lower risk of
barotrauma (RR, 0.43; 95% CI, 0.20 to 0.90; P = 0.02;
I2 = 0; Figure 3), and increased VFDs over a period of
Figure 1 Summary of evidence search and selection . Flow
diagram showing steps of study selection.
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28 days (MD, 1.91 days; 95% CI, 0.28 to 3.55; P = 0.02;
I2 = 0), but no appreciable difference in the duration of
mechanical ventilation for all patients (MD, 1.21; 95%
CI, 4.23 to 1.81; P = 0.43; I2 = 0; Figure 4) or specifically
among survivors (MD, 0.25 days; 95% CI, 5.48 to 5.99; P =
0.93; I2 = 49%; Figure 4). Only one trial reported ICU
length of stay, which did not differ between groups (mean
difference, 1.80 days; 95% CI, 5.93 to 2.33; P = 0.39), even
when the analysis was limited to survivors (mean differ-
ence, 2.90 days; 95% CI, 7.86 to 2.06; P = 0.25).
All three trials reported ICU-acquired weakness. One
trial used a validated measure (Medical Research Council
(MRC) score) to screen systematically for ICU-acquired
weakness [14]. The other two trials used a clinical assess-
ment of “quadriparesis” as a definition of ICU-acquired
weakness. The use of NMBA was not associated with
increased risk of ICU-acquired weakness (RR, 1.08; 95%
CI, 0.83 to 1.41; P = 0.57; I2 = 0; Figure 5). In total, 190
patients included in this review received corticosteroid
therapy during the study period of cisatracurium
infusion.
Oxygenation was assessed by using PaO2/FiO2 at var-
ious time points after randomization. The pooled analy-
sis suggested better PaO2/FiO
2 in the NMBA group at
Table 1 Characteristics of included trials
Study Number
(sites)
Target patients Experimental intervention Control intervention Lung protection
Gainnier
2004 [12]
56 ARDS 48-hour infusion cisatracurium 48-hour infusion placebo
(bedside nurse not blinded)
ARMA protocol; no
weaning protocol
(4) PaO2/FiO2 < 150 (weight-based, and adapted to
peripheral nerve stimulation)




36 ARDS 48-hour infusion cisatracurium 48-hour infusion placebo
(bedside nurse not blinded)
ARMA protocol; no
weaning protocol
(3) Intubated < 48
hours







340 ARDS 48-hour infusion cisatracurium 48-hour infusion placebo ARMA protocol;
weaning protocol
(20) PaO2/FiO2 < 150 (high-dose, with no peripheral nerve
stimulation)
Eligible < 48 hours
Exclude prior NMBA
ARDS, Acute respiratory distress syndrome; NMBA, neuromuscular blocking agent; ARMA, the Acute Respiratory Distress Syndrome Network. Ventilation with
lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome [4].
Table 2 Methodologic quality of trials
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24, 48, and 72 hours after randomization, but only the
result at 48 hours was statistically significant (Figure 6).
Results of this review were consistent across the three
trials; however, we proceeded with planned analyses to
test their robustness. With respect to the effects of NMBA
on hospital mortality, we found no interactions with study
risk of bias, etiology of ARDS as sepsis versus other, or
with severity of hypoxemia (Table 4). Sensitivity analyses
by using fixed-effects models, pooled odds ratios, and
pooled absolute risk difference generated similar results,
with statistically significant reductions in hospital mortal-
ity (data not shown). Although the trial by Papazian et al.
[14] was the largest and contributed the greatest weight to
the analysis of hospital mortality, the result remained sta-
tistically significant in a post hoc sensitivity analysis
excluding this trial (RR, 0.63; 95% CI, 0.43 to 0.92; P =
0.02; I2 = 0).
Table 3 summarizes the quality of the totality of evi-
dence in this review. Overall, we judged the quality of evi-
dence related to mortality as moderate in light of the
limitations in blinding, and the possibility of publication
bias. We judged the quality of evidence related to ICU-
acquired weakness as weak.
Discussion
In this meta-analysis, we found that the treatment of
critically ill adults with a 48-hour continuous infusion of
cisatracurium besylate consistently reduced the risk of
death at 28 days, ICU discharge, and hospital discharge,
reduced the risk of barotrauma, and did not affect the
duration of mechanical ventilation or the risk of ICU-
acquired weakness.
In terms of the mortality reduction associated with
NMBA therapy, our findings are large and robust. We
determined that for every nine adults with ARDS receiv-
ing cisatracurium therapy, one additional life is saved
during the first 90 days in hospital. This magnitude of
effect is larger than that achieved with low-tidal-volume
ventilation [25]. Moreover, sensitivity analyses using
odds ratios or absolute risk difference produced similar
statistically significant findings. Duration of mechanical
ventilation was not significantly different between
groups, including groups of patients who survived
(Figure 4). However, VFDs were increased in the cisatra-
curium group, as a result of competing risks of death
and duration of ventilation, both of which are integrated
into this outcome.
Figure 2 Mortality. Forest plot comparing neuromuscular blockers and placebo for the following outcomes: 28 days, ICU, and hospital
(truncated at 90 days), results are shown by using random-effects model with relative risk and 95% confidence interval.
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The present systematic review builds on the similar
findings of a recent review by Neto et al. [26]. We ana-
lyzed important new and previously unpublished data
about hospital mortality, an outcome that carries more
weight in clinical decision making and clinical-practice
guidelines. Moreover, we present additional subgroup
analyses addressing severity of hypoxemia and etiology of
ARDS, as well as more-complete analyses related to the
duration of ventilation.
Clinical observations and systematic research both sup-
port the notion that NMBA therapy improves oxygenation
among critically ill patients with ARDS [12,27], although
the mechanism leading to this effect is not entirely clear.
In terms of lung mechanics, better synchrony may lead to
more-uniform lung recruitment, improved compliance,
better gas exchange, and better systemic oxygenation.
With respect to lung inflammation, it is plausible that
improved control of inspiratory volumes and pressures
reduces volutrauma, while better control of expiratory
volumes and pressures reduces atelectrauma; the result
being less pulmonary and systemic inflammation [4]. The
latter hypothesis is supported by one of the three trials
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Very weakcde
Control: 62/208 (30%)
ICU Length of stay 1
(339)
n/a MD, 1.80 (CI, 5.93 to 2.33);
P = 0.39
n/a n/a
CI, confidence interval; ICU, intensive care unit; MD, mean difference; n/a, not applicable; RR, risk ratio. aPooled relative risk among RCTs. bThe corresponding risk
(and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). cRated down
for incomplete blinding. dRated down for ascertainment bias (limited assessment of weakness in two trials). eRated down for imprecision. GRADE, Working Group
grades of evidence; High quality, further research is very unlikely to change our confidence in the estimate of effect; Moderate quality, further research is likely to
have an important impact on our confidence in the estimate of effect and may change the estimate; low quality, Further research is very likely to have an
important impact on our confidence in the estimate of effect and is likely to change the estimate; very low quality, we are very uncertain about the estimate.
Figure 3 Barotrauma. Forest plot comparing neuromuscular blockers and placebo for barotrauma outcome; results are shown by using
random-effects model with relative risk and 95% confidence interval.
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included in this review, which demonstrated a significant
reduction in pulmonary levels of IL-6, IL-8, and IL-1B in
cisatracurium-treated patients, along with improved oxy-
genation [13]. Whatever the mechanism, this review found
a corresponding improvement in early mortality.
A prominent criticism of this literature has been the
relative lack of caregiver blinding, even in the largest and
most recent trial, which was placebo controlled. In this
trial, bedside clinicians confirmed the adequacy of deep
sedation (defined as no response on glabellar tap) before
initiating a high-dose infusion of either cisatracurium
besylate or an identical-appearing placebo. Thereafter,
clinicians did not monitor the depth of paralysis with per-
ipheral nerve stimulation; rather, they monitored airway
pressures and, when plateau pressures exceeded 32 cm
H2O (for more than 10 minutes, and despite increased
sedation) in either group, an open-label intravenous bolus
of cisatracurium was administered. We believe that the
majority of patients with severe ARDS who have no
response to glabellar tap are unlikely to initiate sponta-
neous breaths, and, for that majority of patients, caregivers
remained blinded. In the application of this protocol out-
side a research setting, monitoring the depth of paralysis
with peripheral nerve stimulation would serve to prevent
unnecessarily high dosing of cisatracurium besylate and,
accordingly, possibly reduce any adverse effects.
The possibility of a link between neuromuscular block-
ade and risk of ICU-acquired weakness poses a strong
deterrent to NMBA therapy in current management of
adult ARDS [15,16,28,29]. The strongest clinical research
supporting this association includes four retrospective
studies (n = 481) in the management of severe asthma
[15]. These studies were confounded by concurrent,
high-dose glucocorticosteroid therapy. In contrast,
slightly less than one half of the patients in this review
received corticosteroid therapy during the study infusion
of cisatracurium besylate, at lower doses than those
administered for acute asthma. Moreover, the observa-
tional studies in asthma generally lacked systematic
screening for ICU-acquired weakness. Common conclu-
sions from the asthma literature are that (a) prolonged
quadriparesis may be related to the dose and duration of
Figure 4 Duration of mechanical ventilation. Forest plot comparing neuromuscular blockers and placebo for the duration of mechanical
ventilation in all patients and in survivors; results are shown by using random-effects model with relative risk and 95% confidence interval.
Figure 5 ICU-acquired weakness. Forest plot comparing neuromuscular blockers and placebo for ICU-acquired weakness outcome; results are
shown by using random-effects model with mean difference and 95% confidence interval.
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neuromuscular blockade, (b) particularly in the settings
of coexistent renal or hepatic dysfunction, and (c) a class
effect may exist (although the data are inconsistent) with
amino steroid NMBAs (for example, pancuronium,
vecuronium) posing a higher risk of ICU-acquired weak-
ness than benzylisoquinolones (for example, atracurium,
cisatracurium).
In contrast to the prior literature in asthma, we reviewed
randomized trials of patients with severe ARDS. Our
review found no apparent increase in ICU-acquired weak-
ness with cisatracurium therapy. The definition of this
outcome in two of the three trials was based simply on
clinically detectable quadriparesis [12,13], which may lack
both sensitivity and specificity; however, the most recent
and largest trial used the validated Medical Research
Council score [28], and found identical risk of ICU-
acquired weakness whether or not patients received
NMBA therapy. Future studies could use the same mea-
sure over a more protracted period of time, and supple-
ment these assessments with electrophysiologic testing.
The strengths of this review include adherence to a
predetermined review protocol, a comprehensive litera-
ture search, duplicate independent judgments about
study eligibility and risk of bias, and collaboration with
authors of the primary studies after the review protocol
had been established.
Figure 6 Oxygenation at 24 to 72 hours. Forest plot comparing neuromuscular blockers and placebo for oxygenation outcome (measured by
using PaO2/FiO2 at 24 to 72 hours after randomization); results are shown by using random-effects model with mean difference and 95%
confidence interval.
Table 4 Subgroup analyses for hospital mortality outcome
Subgroup Number of patients (n) Relative risk (95% CI) P value (interaction between groups)
Methodologic quality of trials
Low risk of bias 339 0.78 (0.59 to 1.03) 0.38
High/unclear risk of bias 92 0.63 (0.43 to 0.92)
Cause of ARDS
Sepsis 311 0.72 (0.54 to 0.94) 0.83
Other causes 120 0.76 (0.47 to 1.24)
PaO2/FiO2
≥ 100 to 200 256 0.77 (0.57 to 1.03) 0.87
< 100 175 0.74 (0.51 to 1.06)
ARDS, acute respiratory distress syndrome; PaO2/FiO2, ratio of partial arterial pressure of oxygen to fraction of inspired oxygen.
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Four noteworthy limitations exist. First, it is conceivable
that incomplete blinding in two trials might have led to
inflated estimates of benefit. Second, we were unable to
assess for publication bias. Third, it is uncertain whether
the results of this review are applicable to cisatracurium
besylate only, to all benzylisoquinolone agents, or to all
neuromuscular blocking agents and, in addition, we were
unable to investigate optimal dosing strategies. Finally,
these findings may not be applicable to centers in which
the care of adults with ARDS differs significantly from the
care provided in France, where the 20 centers involved in
these studies were located.
Current clinical management of critically ill adults with
ARDS commands further direction on the role for NMBA
therapy, which has become an important part of the arma-
mentarium for severe hypoxemia [6]. In the three recent
clinical trials of high PEEP for the management of adult
acute lung injury and ARDS, in which NMBA therapy was
not protocolized, more than one half of 2,299 patients
received neuromuscular blockade at some time during
their study, for a median of 2.5 days [6]. Interestingly, dur-
ing a decade of randomized trials comparing low-tidal-
volume ventilation with traditional tidal volumes, signifi-
cantly more patients managed with low-tidal-volume stra-
tegies received NMBA therapy (RR, 1.37; 95% CI, 1.04 to
1.82; P = 0.030) [5], suggesting that NMBA may already
play a very important role in lung-protective ventilation.
Conclusions
In summary, results of this review suggest that a 48-
hour continuous infusion of cisatracurium besylate for
patients with severe ARDS reduces 28-day, ICU, and
hospital mortality, as well as barotrauma, without
increasing the risk of ICU-acquired weakness. Although
these findings were derived from a single group of
investigators at multiple centers across France, further
international multicenter trials maybe warranted to con-
firm the generalizability of these findings. Meanwhile,
many clinicians have adopted NMBA therapy into their
routine management of adult ARDS. Given that mortal-
ity is the critical outcome of interest in this setting, our
findings provide new support for a short-term infusion
of cisatracurium besylate for critically ill adults with
severe ARDS.
Key messages
• Few published studies suggested that the use of
neuromuscular blocking agents improves lung
mechanics, patient-ventilator asynchrony, and
reduces inflammatory mediators in patients with
ARDS.
• A recently published randomized controlled trial
suggested that the use of cisatracurium in patients
with ARDS may reduce mortality.
• A systematic review and meta-analysis of RCTs
examining the effect of using NMBA (cisatracurium)
resulted in a significant reduction in risk of death at
28 days and at ICU and hospital discharge when
compared with placebo or no intervention. The risk
of barotrauma was reduced with no increase in the
risk of ICU-acquired weakness.
Additional material
Additional file 1: Search strategy and references: Contains
electronic database search strategy (search terms) and reference
list of all excluded full-text articles that were assessed for eligibility.
Abbreviations
ARDS: acute respiratory distress syndrome; CI: confidence interval; FiO2:
fraction of inspired oxygen; GRADE: grading of recommendations
assessment, development, and evaluation; ICU: intensive care unit; MD:
mean difference; MRC score: medical research council score; NMBA:
neuromuscular blocking agent; PEEP: positive end-expiratory pressure; PO2:
partial pressure of oxygen in the blood; RR: relative risk or risk ratio.
Authors’ contributions
WA and MA conceived the idea and designed the study. WA and MA
performed data abstraction. LP and J-M F provided data from original studies.
WA conducted the analysis. WA, RJ, and MM drafted the article. All of the
authors critically revised the manuscript and agreed on the submitted version.
Competing interests
Laurent Papazian received grants for ACURASYS trial from GlaxoSmithKline
and honoraria for advice or public speaking for Faron (June 2011). Other
authors declare that they have no competing interests.
Acknowledgements
The authors of this review acknowledge the assistance of Anees Sindi in
hand-searching conference proceedings for unpublished data.
Author details
1Department of Medicine, McMaster University Medical Centre, 1200 Main
Street West, Hamilton, Ontario, L8N 3Z5, Canada. 2Department of Critical
Care and Emergency Medicine, King Fahad Hospital, Aqrabia Street,
Alkhober, 31952, Kingdom of Saudi Arabia. 3Department of Clinical
Epidemiology and Biostatistics, McMaster University Medical Centre, 1200
Main Street West, Hamilton, Ontario, L8N 3Z5, Canada. 4Service de
Réanimation des Détresses Respiratoires et Infections Sévères, Assistance
Publique Hôpitaux de Marseille, URMITE CNRS-UMR 6236, Aix-Marseille
University, Marseille, 13015, France. 5Division of Pulmonary and Critical Care
Medicine, Johns Hopkins University, 5501 Hopkins Bayview Circle, Baltimore,
MD 21224, USA.
Received: 13 October 2012 Accepted: 11 March 2013
Published: 11 March 2013
References
1. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ,
Hudson LD: Incidence and outcomes of acute lung injury. N Engl J Med
2005, 353:1685-1693.
2. MacCallum NS, Evans TW: Epidemiology of acute lung injury. Curr Opin
Crit Care 2005, 11:43-49.
3. Erickson SE, Martin GS, Davis JL, Matthay MA, Eisner MD: Recent trends in
acute lung injury mortality: 1996-2005. Crit Care Med 2009, 37:1574-1579.
4. The Acute Respiratory Distress Syndrome Network: Ventilation with lower
tidal volumes as compared with traditional tidal volumes for acute lung
injury and the acute respiratory distress syndrome. N Engl J Med 2000,
342:1301-1308.
Alhazzani et al. Critical Care 2013, 17:R43
http://ccforum.com/content/17/2/R43
Page 9 of 10
5. Burns KE, Adhikari NK, Slutsky AS, Guyatt GH, Villar J, Zhang H, Zhou Q,
Cook DJ, Stewart TE, Meade MO: Pressure and volume limited ventilation
for the ventilatory management of patients with acute lung injury: a
systematic review and meta-analysis. PloS One 2011, 6:e14623.
6. Briel M, Meade M, Mercat A, Brower RG, Talmor D, Walter SD, Slutsky AS,
Pullenayegum E, Zhou Q, Cook D, Brochard L, Richard JC, Lamontagne F,
Bhatnagar N, Stewart TE, Guyatt G: Higher vs lower positive end-
expiratory pressure in patients with acute lung injury and acute
respiratory distress syndrome: systematic review and meta-analysis.
JAMA 2010, 303:865-873.
7. Sud S, Friedrich JO, Taccone P, Polli F, Adhikari NK, Latini R, Pesenti A,
Guerin C, Mancebo J, Curley MA, Fernandez R, Chan MC, Beuret P,
Voggenreiter G, Sud M, Tognoni G, Gattinoni L: Prone ventilation reduces
mortality in patients with acute respiratory failure and severe
hypoxemia: systematic review and meta-analysis. Intensive Care Med 2010,
36:585-599.
8. Hansen-Flaschen JH, Brazinsky S, Basile C, Lanken PN: Use of sedating
drugs and neuromuscular blocking agents in patients requiring
mechanical ventilation for respiratory failure: a national survey. JAMA
1991, 266:2870-2875.
9. Rhoney DH, Murry KR: National survey of the use of sedating drugs,
neuromuscular blocking agents, and reversal agents in the intensive
care unit. J Intensive Care Med 2003, 18:139-145.
10. Christensen BV, Thunedborg LP: Use of sedatives, analgesics and
neuromuscular blocking agents in Danish ICUs 1996/97: a national
survey. Intensive Care Med 1999, 25:186-191.
11. Samuelson KA, Larsson S, Lundberg D, Fridlund B: Intensive care sedation
of mechanically ventilated patients: a national Swedish survey. Intensive
Crit Care Nursing 2003, 19:350-362.
12. Gainnier M, Roch A, Forel JM, Thirion X, Arnal JM, Donati S, Papazian L:
Effect of neuromuscular blocking agents on gas exchange in patients
presenting with acute respiratory distress syndrome. Crit Care Med 2004,
32:113-119.
13. Forel JM, Roch A, Marin V, Michelet P, Demory D, Blache JL, Perrin G,
Gainnier M, Bongrand P, Papazian L: Neuromuscular blocking agents
decrease inflammatory response in patients presenting with acute
respiratory distress syndrome. Crit Care Med 2006, 34:2749-2757.
14. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A,
Jaber S, Arnal JM, Perez D, Seghboyan JM, Constantin JM, Courant P,
Lefrant JY, Guerin C, Prat G, Morange S, Roch A: Neuromuscular blockers
in early acute respiratory distress syndrome. N Engl J Med 2010,
363:1107-1116.
15. Leatherman JW, Fluegel WL, David WS, Davies SF, Iber C: Muscle weakness
in mechanically ventilated patients with severe asthma. Am J Respir Crit
Care Med 1996, 153:1686-1690.
16. Garnacho-Montero J, Madrazo-Osuna J, Garcia-Garmendia JL, Ortiz-Leyba C,
Jimenez-Jimenez FJ, Barrero-Almodovar A, Garnacho-Montero MC, Moyano-
Del-Estad MR: Critical illness polyneuropathy: risk factors and clinical
consequences: a cohort study in septic patients. Intensive Care Med 2001,
27:1288-1296.
17. Murray MJ, Cowen J, DeBlock H, Erstad B, Gray AW Jr, Tescher AN,
McGee WT, Prielipp RC, Susla G, Jacobi J, Nasraway SA Jr, Lumb PD: Clinical
practice guidelines for sustained neuromuscular blockade in the adult
critically ill patient. Crit Care Med 2002, 30:142-156.
18. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K,
Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H,
Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J,
Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL:
Surviving Sepsis campaign: international guidelines for management of
severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327.
19. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M,
Legall JR, Morris A, Spragg R: The American-European Consensus
Conference on ARDS: definitions, mechanisms, relevant outcomes, and
clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824.
20. PapersFirst. [http://library.mcmaster.ca/articles/papersfirst].
21. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD,
Savovic J, Schulz KF, Weeks L, Sterne JA: The Cochrane Collaboration’s
tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928.
22. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials
1986, 7:177-188.
23. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis
detected by a simple, graphical test. BMJ 1997, 315:629-634.
24. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P,
Schunemann HJ: GRADE: an emerging consensus on rating quality of
evidence and strength of recommendations. BMJ 2008, 336:924-926.
25. Putensen C, Theuerkauf N, Zinserling J, Wrigge H, Pelosi P: Meta-analysis:
ventilation strategies and outcomes of the acute respiratory distress
syndrome and acute lung injury. Ann Intern Med 2009, 151:566-576.
26. Neto AS, Pereira VG, Esposito DC, Damasceno MC, Schultz MJ:
Neuromuscular blocking agents in patients with acute respiratory
distress syndrome: a summary of the current evidence from three
randomized controlled trials. Ann Intensive Care 2012, 2:33.
27. Lagneau F, D’Honneur G, Plaud B, Mantz J, Gillart T, Duvaldestin P, Marty J,
Clyti N, Pourriat JL: A comparison of two depths of prolonged
neuromuscular blockade induced by cisatracurium in mechanically
ventilated critically ill patients. Intensive Care Med 2002, 28:1735-1741.
28. Herridge MS: Building consensus on ICU-acquired weakness. Intensive
Care Med 2009, 35:1-3.
29. Griffiths RD, Hall JB: Intensive care unit-acquired weakness. Crit Care Med
2010, 38:779-787.
doi:10.1186/cc12557
Cite this article as: Alhazzani et al.: Neuromuscular blocking agents in
acute respiratory distress syndrome: a systematic review and meta-
analysis of randomized controlled trials. Critical Care 2013 17:R43.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Alhazzani et al. Critical Care 2013, 17:R43
http://ccforum.com/content/17/2/R43
Page 10 of 10
